Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Primary liver tumors are mainly represented by hepatocellular carcinoma (HCC), one of the most aggressive and resistant forms of cancer. Liver tumorigenesis is characterized by an accumulation of epigenetic abnormalities, leading to gene extinction and loss of hepatocyte differentiation. The aim of this work was to investigate the feasibility of converting liver cancer cells toward a less aggressive and differentiated phenotype using a process called epigenetic reconditioning. Here, we showed that an epigenetic regimen with non-cytotoxic doses of the demethylating compound 5-azacytidine (5-AZA) promoted an anti-cancer response by inhibiting HCC cell tumorigenicity. Furthermore, epigenetic reconditioning improved sorafenib response. Remarkably, epigenetic treatment was associated with a significant restoration of differentiation, as attested by the increased expression of characteristic hepatocyte markers in reconditioned cells. In particular, we showed that reexpression of these epigenetically silenced liver genes following 5-AZA treatment or after knockdown of DNA methyltransferase 1 (DNMT1) was the result of regional CpG demethylation. Lastly, we confirmed the efficacy of HCC differentiation therapy by epigenetic reconditioning using an in vivo tumor growth model. In summary, this work demonstrates that epigenetic reconditioning using the demethylating compound 5-AZA shows therapeutic significance for liver cancer and is potentially attractive for the treatment of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“Two large-scale phase III clinical trials have reported improvement in the survival of advanced HCC patients.(46) However, the survival benefit of sorafenib treatment is limited because HCC cells frequently develop drug resistance.”
BackgroundJones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · cited 1×
“Among human detoxification enzymes, CYP3A4 plays the most important role in the metabolism of xenobiotics and commercial drugs.(25) As described above, HepG2 cells first underwent an epigenetic reconditioning regimen for 2 weeks (Figure 2B).”
BackgroundEl-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529 · cited 1×
“However, surgical resection and liver transplantation remain the only effective therapeutic options for liver cancer.(5) In addition, HCC prognosis remains”
BackgroundCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Chromatin modification and epigenetic reprogramming in mammalian development
Li, E. (2002) · Nature Reviews Genetics · doi:10.1038/nrg887 · Cited by 1,900
Saxonov, S., Berg, P., & Brutlag, D. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510310103 · Cited by 1,401
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288 · cited 1×
“The use of these hypomethylating agents has shown efficacy in treating myelodysplastic syndromes(34) and has gained attention for the treatment of solid tumors.(35,36) Tsai and coworkers(20) reported that transient exposure of leukemic and epithelial tumor cells to low doses of 5-AZA and 5-AZA-dC was sufficient to pro…”
BackgroundTurcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
Cited by
Tang, W., Chen, Z., Zhang, W., Cheng, Y., Zhang, B., Wu, F., Wang, Q., Wang, S., Rong, D., Reiter, F. P., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0187-x · Cited by 997
Epigenetics in hepatocellular carcinoma
Nagaraju, G. P., Dariya, B., Kasa, P., Peela, S., & El-Rayes, B. F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.017 · Cited by 339
The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
Xia, S., Pan, Y., Liang, Y., Xu, J., & Cai, X. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102610 · Cited by 297
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126
“In response to these agents TSG expression is reactivated and HCC cells partially recover their hepatocellular differentiation, becoming less tumourigenic and more sensitive to sorafenib.(142,143) Decitabine was tested in patients with advanced HCC at low doses, showing favourable toxicity and signs of clinical benefi…”
BackgroundRecalde, M., Gárate-Rascón, M., Herranz, J. M., Elizalde, M., Azkona, M., Unfried, J. P., Boix, L., Reig, M., Sangro, B., Fernández-Barrena, M. G., et al. (2022) · Cancers · doi:10.3390/cancers14092048 · Cited by 14
Metadata
- Authors
- Gailhouste, L., Liew, L. C., Yasukawa, K., Hatada, I., Tanaka, Y., Nakagama, H., & Ochiya, T.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 26
- Issue
- 7
- Pages
- 1840-1854
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2799466910
- Cited by
- 77
- References
- 12
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells. https://app.cochat.ai/papers/10.1016/j.ymthe.2018.04.018
- The paper
- Gailhouste, L., Liew, L. C., Yasukawa, K., Hatada, I., Tanaka, Y., Nakagama, H., & Ochiya, T. (2018). Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2018.04.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.